Results 181 to 190 of about 29,446 (242)

Risk of Safety Events in Vitiligo Patients: A Retrospective Real-World Data Study in the US. [PDF]

J Dermatol
Cook K, Elbuluk NM, Adiri R, Lejeune A, Edwards T, Gianfrancesco MA, Kelly SP, Lukic T, Nagy E, Kurosky SK, Napatalung L, Hamzavi I.   +11 more
europepmc   +1 more source

Segmental Vitiligo and Somatic Mosaicism: From Pathogenesis to Therapeutics. [PDF]

Ann Dermatol
Oh J, Oh SH.
europepmc   +1 more source

Tinea barbae following ruxolitinib cream application in a vitiligo patient: a case report. [PDF]

Front Med (Lausanne)
Romagnuolo M, Rossi LC, Tavoletti G, Germiniasi F, Grancini A, Moltrasio C, Marzano AV, Alberti-Violetti S.   +7 more
europepmc   +1 more source

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo.

Indian J Dermatol
Jagadeesan S, Prasad N, Duraiswamy P, Panicker VV.   +3 more
europepmc   +1 more source

Analysis of the profiles of human endogenous retroviruses W, K, and H and the systemic inflammatory status in vitiligo patients: insights on the dynamics of endogenous retroviral expression and its interplay with inflammatory response. [PDF]

Front Cell Infect Microbiol
Santos SN, Silva DC, Fernandes ME, da Silva MD, Santos MKO, França CN, do Amaral JB, Shio MT, Facina ADS, Bachi ALL, Nali LHDS.   +10 more
europepmc   +1 more source

Neuropeptide Y drives vitiligo progression via NPYR-mediated NF-κB activation: a novel therapeutic target. [PDF]

Sci Rep
Tian B, Wang Y, Liu B, Shen J, Zhang Y, Gui J, Hu W, Zhou B, Jin A, Chen J, Liu H, Li Q.   +11 more
europepmc   +1 more source

Cross-Cultural Beliefs and Stigmatization in Vitiligo: A Systematic Review. [PDF]

J Cosmet Dermatol
Ma S, Zieneldien T, Tan IJ, Jafferany M.
europepmc   +1 more source

Exploring the Role of Radix Polygalae in Melanogenesis Related to Vitiligo: A Network Pharmacology Analysis with in vitro Validation. [PDF]

Clin Cosmet Investig Dermatol
Zhu L, Liang Y, Jiang L, Fu C, Dai X, Guo H, Zeng Q, Hu S, Chen J.   +8 more
europepmc   +1 more source